Andrea Riposati from Dante Labs in the US presented at London Calling 2019 on “Human long-read whole genome sequencing: applications and results.” Riposati is the co-founder and CEO of Dante Labs. They presented a case of a patient who had suffered 45 years without a diagnosis. Dante Labs provided whole genome sequencing and pharmacogenomics lab. Dante Labs has offices in Italy and New York. They are a Nanopore-certified Service Provider. Riposati noted that Dante Labs is the first commercial long-read human whole genome sequencing service using the PromethION. They now do forty-eight samples at a time on the PromethION 48. They guarantee 30X with an average N50 >20,000 bp. On average, users are getting 90+ Gbases of data per sample. Riposati explained that they use saliva. The read length histogram showed a variety of lengths. Dante Labs has standardized collection protocols. Their sequencing reports highlight large sequence variants and other mutations. The company is accepting applications for Epilepsy whole genome sequencing study. Another case study Riposati presented was a woman who had her whole genome sequenced and years later used the data to help with treatment after breast cancer diagnosis. Riposati also emphasized that Dante Labs actively collaborates with academic labs and other partners. I am now interested in learning what goes into becoming a certified Nanopore service provider. Also, I am curious about the reports produced by Dante Labs.
